Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

What are Viruses?00:50

What are Viruses?

128.1K
Overview
128.1K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

274
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
274
Hepatic Portal System01:21

Hepatic Portal System

5.8K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.8K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

243
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
243
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

564
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
564
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

309
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
309

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hantavirus stability and inactivation.

PLoS neglected tropical diseases·2026
Same author

Cystobactamid off-target profiling reveals favorable safety, superoxide reduction, and SCARB1 inhibition in eukaryotes.

npj drug discovery·2026
Same author

Respiratory syncytial viral load drives ciliated cell dedifferentiation and suppresses antiviral immunity.

Science advances·2026
Same author

Augmenting hepatitis C E1E2 glycoprotein antibody detection via an alternative lectin-assisted mannose-binding ELISA.

Virology·2026
Same author

From discovery to therapy: The role of HSPB1 in HBV persistence.

Journal of hepatology·2025
Same author

A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma.

Cancer cell·2025
Same journal

Environmental microbes as modulators of plant volatile landscapes: Implications for plant-insect chemical communication.

Trends in microbiology·2026
Same journal

Beyond AMGs: Phage-encoded transcription and sigma factors as understudied virocell reprogramming tools.

Trends in microbiology·2026
Same journal

Cronobacter spp.

Trends in microbiology·2026
Same journal

Anaerobic lignin deconstruction: A game changer for lignocellulosic biorefineries.

Trends in microbiology·2026
Same journal

Critical role of the inflammatory rheostat in influenza-associated pulmonary aspergillosis.

Trends in microbiology·2026
Same journal

Structure-based prokaryotic transcription shapes adaptation and host-invader interplay.

Trends in microbiology·2026
See all related articles

Related Experiment Video

Updated: Jan 30, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.7K

Hepatitis C Virus.

Thomas Pietschmann1, Richard J P Brown1

  • 1Division of Experimental Virology, Twincore Center for Experimental and Clinical Infection Research, Feodor-Lynen-Straße 7-9, 30625 Hannover, Germany.

Trends in Microbiology
|February 3, 2019
PubMed
Summary
This summary is machine-generated.

Hepatitis C virus (HCV) infection causes chronic liver disease and cancer. Highly effective direct-acting antiviral therapies cure over 95% of patients, but reinfection is possible, highlighting the need for a vaccine.

Keywords:
HCVantiviral therapyinfectionliver disease

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.0K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

Related Experiment Videos

Last Updated: Jan 30, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.7K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.0K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

Area of Science:

  • Virology
  • Hepatology
  • Immunology

Background:

  • Hepatitis C virus (HCV) is a significant global health concern, primarily infecting liver cells and leading to chronic disease.
  • HCV establishes chronic infections in 70% of cases, potentially progressing to liver cirrhosis and hepatocellular carcinoma.
  • Annual mortality from HCV infection is approximately 400,000 globally, with 1.7 million new infections each year.

Purpose of the Study:

  • To review the mechanisms of HCV infection and immune evasion.
  • To discuss the efficacy of current direct-acting antiviral (DAA) therapies.
  • To highlight the ongoing challenge of reinfection and the development of a prophylactic vaccine.

Main Methods:

  • Review of scientific literature on Hepatitis C virus.
  • Analysis of current treatment strategies, including direct-acting antivirals (DAAs).
  • Examination of viral targets (NS3-4A protease, NS5A, NS5B) of DAAs.
  • Discussion of epidemiological data and vaccine development.

Main Results:

  • Direct-acting antivirals (DAAs) targeting viral proteins NS3-4A, NS5A, and NS5B offer high cure rates (>95%).
  • Despite effective treatments, approximately 71 million people remain chronically infected worldwide.
  • Cure does not confer immunity, leaving patients susceptible to reinfection.

Conclusions:

  • Combination DAA therapy represents a highly effective treatment for Hepatitis C virus infection.
  • The lack of protective immunity post-cure necessitates continued prevention strategies.
  • A prophylactic vaccine for HCV is crucial for long-term global disease eradication.